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Abstract
Background
C-Tb, an ESAT-6/CFP-10-based skin test, has similar sensitivity for active TB compared to
tuberculin skin test (TST) and QuantiFERON-TB-Gold-In-Tube (QFT). However, data are
limited in children and HIV-infected persons.
Methods
Asymptomatic South African contacts <5 years (n = 87; HIV-uninfected), or symptomatic
individuals of all ages presenting to clinics with suspected TB (n = 1003; 30% HIV-infected)
were recruited from eight South African centres. C-Tb and TST were allocated to either fore-
arm double blinded. Samples for QFT were collected in parallel, and test-positivity rates
were compared.
Results
In participants with microbiologically confirmed TB (n = 75; 45% HIV-infected) sensitivity of
C-Tb, TST and QFT were similar (72% versus 75% versus 73%; p>0.5). All 3 tests had simi-
lar positivity rates in HIV-infected participants with active TB, however, positivity rates were
reduced when CD4 counts were <100 cells/μL. In participants where active TB was
excluded (n = 920), C-Tb (41%), TST (43%), and QFT (44%) also had similar test-positivity
rates. Among asymptomatic contacts aged below five, 32% (28/87) tested positive with C-
Tb and 32% (28/87) with TST (concordance 89%). Overall, C-Tb and TST showed a similar
safety profile.
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Conclusion
C-Tb was safe and showed similar test-positivity rates, compared to TST and QFT, in chil-
dren and HIV-infected persons with active or latent M. tuberculosis infection. These data
inform the utility of C-Tb in clinical practice.
Trial registration
ClinicalTrials.gov NCT01642888.
EudraCT 2011-005078-40.
Introduction
In contrast to active TB, which can be microbiologically proven, latent M. tuberculosis infec-
tion (LTBI) can only be inferred indirectly by the detection of an antigen-specific immune
response, either in the skin through the tuberculin skin test (TST) using purified protein deriv-
ative (PPD), or in vitro using a blood-based interferon-γ release assay (IGRA) [1,2].
One strategy to decrease the burden of TB in low and high TB-burden settings is to
systematically test those with LTBI, at highest risk of progressing to active disease, but are
willing to accept treatment. Risk groups include people living with HIV, and adult and
childhood contacts of active cases of pulmonary TB (PTB) [1,3–5]. However, there are sev-
eral drawbacks of the currently approved tests. The TST may give false-positive reactions
from cross-reactivity with non-tuberculous mycobacteria and previous Bacillus Calmette–
Gue´rin (BCG) vaccination especially if BCG is administered after infancy [6–8]. In HIV
co-infection, the cut-point may need adjustment to mitigate for lower sensitivity. More
recently, the IGRAs QuantiFERON-TB Gold In Tube (QFT; Qiagen, Hilden, Germany) and
T-SPOT.TB (Oxford Immunotec, Abingdon, UK) have become routine tests to diagnose
presumed M.tb infection in low-burden countries, either alone or in combination with TST
[9,10]. The IGRAs are more specific and require only a single visit for phlebotomy. How-
ever, a second visit may often be needed to clarify the result, complete symptom screening
for active TB, and to start LTBI treatment. The IGRAs also have several drawbacks, includ-
ing the need for complex laboratory and sample-transport infrastructure, higher costs,
within person variability, and a high proportion of indeterminate results in advanced HIV
and very young children [11].
C-Tb (Statens Serum Institut, Copenhagen, Denmark) is a highly specific skin test for the
diagnosis of LTBI designed to address some of the drawbacks of TST and IGRAs [12]. C-Tb is
applied and read in the same way as TST, but is based on the antigens ESAT-6 and CFP-10
that are also included in the IGRAs. Due to high specificity, C-Tb uses a universal 5 mm cut-
point induration irrespective of the status of BCG, HIV, or both [13]. In a recent contact trac-
ing trial that included groups with various degrees of exposure to cases of PTB, C-Tb test-posi-
tivity rates were concordant with increasing exposure to TB, and were very highly concordant
with QFT [14].
However, little is known about the value of C-Tb in other risk groups including young chil-
dren and persons living with HIV [3,15,16]. To address this question, we conducted a phase 3
trial that included participants of all ages (with varying HIV status). Participants included
those with suspected active TB, asymptomatic children <5 years old that were close contacts
of cases with active PTB, and healthy older children served as community-based control
C-Tb in children and HIV-infected persons
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group. As there is no microbiological gold standard for LTBI, as in previously published evalu-
ation studies [11,17], sensitivity was determined in active TB [13], with the presumption that
sensitivity would be similar or possibly better in LTBI (given that active TB is an immunosup-
pressive state).
Materials and methods
Trial design and participants
The trial was a double-blind, split-body design with randomized injections of C-Tb versus
TST in either forearm. The trial was conducted in eight South African sites from September
05, 2012 to September 30, 2014. 1003/1190 of those enrolled were cases with suspected TB (0–
65 years; 30% HIV-infected), while the remainder comprised 87 asymptomatic PTB contacts
aged below five, and 100 healthy controls (5–11 years old; Fig 1). The latter was to infer the
impact of recent exposure on skin test responses using ‘supposedly’ non-exposed children (no
known contact but within a TB endemic environment where the force of infection is high) as a
reference, and to complete safety evaluations over a range of childhood subgroups (children
with active TB, asymptomatic contacts of active cases, and healthy controls that did not have a
definitive history of exposure).
Those with suspected TB between 0 and 65 years of age presented to primary care clin-
ics with TB symptoms (online data supplement S1 Table). These individuals, after inves-
tigation and follow-up for 28 days, were classified as either active TB cases (culture or
Xpert MTB/RIF positivity served as the reference standard) or non-TB. Participants with
clinical symptoms of TB but with a negative microbiology were included in the non-TB
group, because only microbiologically confirmed TB was regarded gold standard to eval-
uate the sensitivity of the tests. The asymptomatic children aged <5 years were close con-
tacts of a smear positive PTB case defined as more than 6 h contact per day for at least
five days. The trial staff also recruited a healthy control group of children with no known
contact with people infected with M.tb and no symptoms or signs of active TB (as out-
lined above). Subjects with confirmed active TB or AIDS defining diagnosis at screening
were excluded.
Trial procedures
Identical appearing vials of C-Tb and PPD RT 23 (both Statens Serum Institut, Copenhagen,
Denmark, (since 2017 PPD RT 23 is a product held by AJ Vaccines) labelled left or right were
randomized in blocks of 10, and 0.1 mL of each agent was randomly injected in separate arms
immediately one after the other according to the Mantoux technique as previously described
[14]. Induration responses for C-Tb and TST were read 48–72 h after intradermal injection
transversely to the long axis of the forearm with the ballpoint method and a ruler, and docu-
mented with digital images. Indurations1 mm defined a ‘responder’. Samples for Quanti-
FERON-TB-Gold-In-Tube (Qiagen, Hilden, Germany) were collected prior to the skin tests.
The QFT was performed by PathCare (Goodwood, South Africa) according to the manufac-
turer’s instructions. BCG status was determined according to vaccination cards and the pres-
ence of BCG scars. HIV-infection was diagnosed by two alternative positive rapid tests, or one
positive rapid test and a confirmatory ELISA. To limit the amount of blood taken from those
aged<5 years old (as per ethical approval and guidelines), no blood samples for haematology,
biochemistry, QFT or HIV status were collected. The HIV-test result obtained immediately
after birth was used.
C-Tb in children and HIV-infected persons
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Safety assessment
Local and systemic adverse events (AE) were assessed by the trial staff through medical assess-
ments 30 minutes after intradermal injection and at the follow-up visits. Diaries were provided
Fig 1. Overview of the trial participants. These were clinic attendees that on follow-up segregated into those with microbiologically confirmed active
TB and non-TB participants. Efficacy data are presented as number of test positives/n (%).
https://doi.org/10.1371/journal.pone.0204554.g001
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for recording of all AEs experienced until Day 28. Injection site reactions (ISRs) were assigned
to the respective agent, whereas systemic AEs were assigned to both agents.
Objectives and outcomes
The primary trial objective was to assess the performance of C-Tb in children and HIV-
infected persons and to confirm the safety profile. The primary outcome was the test-positivity
rate defined by indurations5 mm for C-Tb and 5 or 15 mm for TST (5 mm if HIV-infected)
[10,12,13]. Secondary outcomes were comparisons of C-Tb, TST, and QFT test positivity. As
there is no gold standard for diagnosing LTBI, we provided comparative test positivity data for
C-Tb, QFT, and TST.
Statistical analysis
Given the lack of a microbiological definition of LTBI, sensitivity was determined in partici-
pants with active TB. In those without active TB (non-TB), C-Tb test-positivity rates were
compared to QFT and TST. Differences in number of test positives were assessed by McNe-
mar’s test for marginal heterogeneity, and in unpaired analyses with Fisher’s exact test or χ2
test. Agreement between tests was assessed with Cohen’s κ coefficient. Given that this trial
addressed patient safety and used within-person randomisation the results have been pre-
sented within the context of the Consort Guidelines. Further details are provided in the online
supplement.
Ethics
The trial was conducted according to the principles expressed in the Declaration of Helsinki.
Written informed consent form were obtained from adult participants and from parents or
legal guardians of children, with additional assent form provided in older children. The trial
was approved by Pharma-Ethics (No. 12024740), University of Cape Town Human Research
Ethics Committee (No. 222/2012), and the Medicines Control Council (No. 20120120). The
trial was part of an agreed Paediatric Investigation Plan, which is in accordance with EU
regulations.
Results
Participants and final diagnosis
During the observation period of 28 days following skin testing, active TB was confirmed
among 75/1003 (7%) with TB symptoms, while 928/1003 (93%) had no microbiological evi-
dence of active TB (non-TB but this included 44 participants with symptoms who were test
negative but empirically treated for TB).
Out of the 928 non-TB cases, two did not receive C-Tb, and six participants were either lost
to follow-up, withdrew consent, or died; thus no induration measurements were recorded in
these participants. None of the three reported deaths were related to the skin tests. Among the
enrolled participants5 years old, 38 (4%) had missing QFT result, and among the remaining
916, 131 (14%) were indeterminate (all due to low IFN-γ levels in the positive control).
Both genders were equally distributed with the median age of 17 years (Table 1). The major-
ity of the trial population was of Black African descent (55–87%). The healthy control group
inadvertently included participants only of mixed race (91%) and of European descent (9%).
There was almost full BCG vaccination coverage among young children. HIV-infection was
mainly observed in adults. Participants with unknown HIV status were all5 years of age.
Median CD4 count in HIV-infected adults was 314 cells/μL (IQR 164–502 cells/μL).
C-Tb in children and HIV-infected persons
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Test performance
Overall. C-Tb showed a positivity rate of 40% (95% CI 38–43%, n = 1182), similar to the
positivity rate of TST (41% [39–44%], n = 1184, p = 0.3456) and the results were concordant in
84% of the participants. QFT was not done in children <5 years old; for those5, QFT
showed a positivity rate of 43% ([40–46%], n = 916), including 131 (14%) indeterminate
results. C-Tb and QFT showed no significant difference among those subjected to dual testing
and the results were concordant in 624 (83%) of the 750 participants with a determinate test
result (p = 0.1987). The impact of age on test readouts is outlined in the online supplement.
Sensitivity, positivity rates and the impact of HIV
Based on the 75 cases with microbiologically confirmed active TB, C-Tb showed a sensitivity
of 72% (95% CI 61–81%), similar to the sensitivity of TST (75% [64–83%], p = 0.8026) and
results were concordant in 59 (79%) of the participants (Table 2, S2 Table). Forty-five percent
(34/75) of the confirmed cases were co-infected with HIV, even though HIV-infection only
constituted 30% (299/1003) of the participants with TB symptoms (Table 1). The sensitivity of
QFT was influenced by five missing results and 14/70 (20%) indeterminate results, mainly (9/
14, 64%) in the HIV-infected group (S2 Table). Seventy-one percent (10/14) of the participants
Table 1. Demographics of the trial population.
ALL Symptomatic Asymptomatic Healthy
controlDiagnosed with active TB Non-TB PTB contact
Trial participants 1190 75 928 87 100
Age (years)
Median (range) 17 (0–65) 32 (0–62) 25 (0–65) 2 (0–4) 8 (5–11)
<5 236 (20) 2 (3) 147 (16) 87 (100) 0 (0)
5–17 366 (31) 13 (17) 253 (27) 0 (0) 100 (100)
18 588 (49) 60 (80) 528 (57) 0 (0) 0 (0)
Sex
Male 589 (49) 40 (53) 465 (50) 43 (49) 53 (53)
Female 601 (51) 35 (47) 463 (50) 44 (51) 47 (47)
Ethnicity
African descent 909 (76) 55 (73) 806 (87) 48 (55) 0 (0)
Other 291 (24) 20 (27) 122 (13) 39 (45) 100 (100)
BCG status
Vaccinated 882 (74) 45 (60) 655 (71) 86 (99) 96 (96)
Not vaccinated 264 (22) 25 (33) 234 (25) 1 (1) 4 (4)
Unknown 44 (4) 5 (7) 39 (4) 0 (0) 0 (0)
HIV
Uninfected 730 (61) 40 (53) 566 (61) 24 (28) 100 (100)
Unknown 161 (14) 1 (1) 97 (10) 63 (72) 0 (0)
Infected 299 (25) 34 (45) 265 (29) 0 (0) 0 (0)
CD4 (HIV-infected) †
<100 40 (14) 12 (35) 28 (11) N.A. N.A.
100 246 (86) 22 (65) 224 (89) N.A. N.A.
Data are presented as n, median (range) or n (%).
Microbiologically confirmed during the trial after skin testing.
†13 missing CD4 count.
https://doi.org/10.1371/journal.pone.0204554.t001
C-Tb in children and HIV-infected persons
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with indeterminate QFT result tested positive with C-Tb, and 79% (11/14) tested positive with
TST. Based on those tested, QFT showed a sensitivity of 59% (41/70), increasing to 73% (41/
56%) if indeterminate results were excluded (Table 2, S2 Table).
In symptomatic non-TB participants, C-Tb showed a positivity rate of 41% (39–44%), simi-
lar to the rate of TST (43% [39–46%], p = 0.298) and QFT (44% [40–47%], p = 0.1105), and
with a concordance of 83% and 79%, respectively (Table 3, S3 Table). All three tests showed
similar positivity rates in HIV-uninfected individuals. However, application of a 5 mm cut-
point for TST in HIV-infected participants was associated with a significantly higher test posi-
tivity rate of 40% (34–46%) compared to C-Tb (34% [29–40%], p = 0.0180) and QFT (26%
[21–32%], p = 0.0004). QFT showed a high number of indeterminate results (111/741 [15%]),
mainly 68/111 (61%) in HIV-infected participants (S3 Table).
In the 245 HIV-infected non-TB participants with available QFT test results, 81 (33%)
tested positive with C-Tb and only 65 (27%) tested positive with QFT (p = 0.0412, Table 3, S3
and S4 Tables). Excluding indeterminate results, QFT positivity rate increased from 27% (65/
245) to 37% (65/177), which was similar to the positivity rate of C-Tb (37% [66/177], S3
Table).
Excluding the 44 participants who were empirically treated for TB from the 920 included in
the non-TB group reduced the C-Tb test positive rate by only 2% points (data not shown).
CD4
All three tests showed reduced test-positivity rates in HIV infected participants with CD4
counts <100 cells/μL (Fig 2). This was observed in both those diagnosed with active TB and
those without active TB (S5 and S6 Tables). For QFT, the rate of indeterminate results reached
a maximum of 65% (17/26) at CD4 counts <100 cells/μL.
Table 2. Sensitivity of C-Tb versus TST (top) and QFT (bottom) in microbiologically confirmed active TB cases.
All HIV-uninfected HIV
co-infected
C-Tb versus TST
N 75 41 34
C-Tb pos. (%) 72.0
(60.9–81.0)
75.6
(60.5–86.4)
67.7
(50.8–81.0)
TST pos. (%) 74.7
(63.7–83.2)
73.2
(57.9–84.4)
76.5
(59.8–87.8)
p-value 0.8026 1.0000 0.3711
C-Tb versus QFT
N 70 38† 32‡
C-Tb pos. (%) 70.0
(58.4–79.5)
73.7
(57.8–85.2)
65.6
(48.2–79.7)
QFT pos. (%) 58.6
(46.9–69.4)
68.4
(52.5–81.0)
46.9
(30.9–63.6)
p-value 0.1175 0.7518 0.1138
Data are presented as % (95% CI). Cut-point for TST was 5 mm in HIV-infected individuals and 15 mm in HIV-
uninfected.
McNemar’s test. In an intention to diagnose principle, QFT indeterminate results were included as negative.
†3 missing QFT. 5/5 QFT indeterminate results were C-Tb positives.
‡2 missing QFT. 5/9 QFT indeterminate results were C-Tb positives.
https://doi.org/10.1371/journal.pone.0204554.t002
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Table 3. Test positive results of C-Tb versus TST (top) and QFT (bottom) in non-TB participants.
All HIV-uninfected HIV-
infected
C-Tb versus TST
N 920 658† 262
C-Tb pos. (%) 41.0
(37.8–44.2)
43.6
(39.9–47.4)
34.4
(28.9–40.3)
TST pos. (%) 42.5
(39.3–45.7)
43.5
(39.7–47.3)
40.1
(34.3–46.1)
p-value 0.2980 1.0000 0.0180
C-Tb versus QFT
N 741 496‡ 245§
C-Tb pos. 46.6
(43.0–50.2)
53.2
(48.8–57.6)
33.1
(27.5–39.2)
QFT pos. 43.7
(40.2–47.3)
52.2
(47.8–56.6)
26.5
(21.4–32.4)
p-value

0.1105 0.6935 0.0412
Data are presented as % (95% CI). Cut-point for TST was 5 mm in HIV-infected individuals and 15 mm in HIV-
uninfected.
McNemar’s test. In an intention to diagnose principle, QFT indeterminate results were included as negative.
†Including 97 participants (5 years of age) with unknown HIV status.
‡Excluding 162 with missing QFT. 15/43 QFT indeterminate results were C-Tb positives.
§17 with missing QFT. 15/68 QFT indeterminate results were C-Tb positives.
https://doi.org/10.1371/journal.pone.0204554.t003
Fig 2. Test positivity rate according to HIV status and CD4 count. The data shown excludes participants with unknown HIV status and healthy
control group. Error bars indicate 95% CI. Cut-point for TST was 5 mm in HIV-infected and 15 mm in others. C-Tb: N = 921 (625 HIV-uninfected, 296
HIV-infected). TST: N = 923 (627 HIV-uninfected, 296 HIV-infected). QFT: N = 818 (126 indeterminate, 538 HIV-uninfected, 280 HIV-infected). Data
specific to the active and non-TB groups are shown in S2–S4 Tables. HIV-uninfected versus HIV-infected p<0.05. †CD4 counts100 cells/μL versus
counts<100 cells/μL in HIV-infected; p<0.05.
https://doi.org/10.1371/journal.pone.0204554.g002
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Children
In children <5 years old TST results are used to guide treatment for active TB. In the present
trial tuberculosis was diagnosed in 12/148 (8%) symptomatic children <5 years old, two of
them were confirmed microbiologically and ten diagnosed according to symptoms or signs of
TB (S7 Table). The two participants diagnosed with active TB both showed indurations15
mm with both skin agents, the youngest at four months of age. Both were close contacts with a
PTB case and presented with cough >2 weeks and drenching night sweats. Those diagnosed
according to clinical symptoms all had TST indurations14 mm, and all but three tested posi-
tive with C-Tb. Of note, 12 children presenting with similar symptoms and positive C-Tb
results were not diagnosed with TB (S6 Table). Four of those had no TST induration.
In the asymptomatic group of children with PTB contacts, 38% (33/87) tested positive with
C-Tb or TST, 23 being positive with the two tests and five positive with either (p = 0.7518, con-
cordance 89%, Table 4).
The youngest participant testing positive with C-Tb had an induration of 11 mm at 71 days
of age, and the youngest responder to TST had an induration of 9 mm at 53 days of age.
C-Tb showed an increasing test positivity rate with age (S8 Table) and with exposure (Fig
3). Thus, 17% (17/100) in the healthy control group tested positive with C-Tb, increasing to
32% (28/87) of the PTB contacts and 87% (13/15) in those with active TB (p<0.0001). Similar
results were found for TST (S9 and S10 Tables).
Induration size
To explore the impact of age and HIV status on skin test performance we compared the indu-
ration sizes of C-Tb and TST responders (defined as skin test induration1 mm) and the
number of non-responders (bimodal distribution). C-Tb showed a minor but significantly
decreased induration from median 21 to 19 mm in HIV-infected participants aged 5–65 years
(p = 0.0148), whereas TST showed a median of 20 mm irrespective of HIV status (S1 Fig). The
number of non-responding active and non-TB participants (5–65 years) increased significantly
from 43% (238/550) in HIV-uninfected to 57% (169/296) in HIV-infected for C-Tb, and from
32% (178/551) to 51% (152/296) for TST (p<0.005). Also age had little influence on the
Table 4. Test positive results of C-Tb versus TST in children<5 years.
Group Age
(years)
N C-Tb pos. (%) TST pos. (%) p-value
Asymptomatic contacts <5 87 32.2
(23.3–42.6)
32.2
(23.3–42.6)
0.7518
0–1 30 23.3
(11.5–41.2)
23.3
(11.5–41.2)
0.6171
2–4 57 36.8
(25.5–49.9)
36.8
(25.5–49.9)
0.6831
Symptomatic
active† and non-TB
<5 148 14.2
(9.4–20.8)
17.6
(12.2–24.6)
0.3320
0–1 69 10.1
(4.7–19.8)
7.3
(2.8–16.2)
0.7237
2–4 79 17.7
(10.7–27.7)
26.6
(18.0–37.3)
0.0455
Data are presented as % (95% CI). Cut-point for TST was 15 mm.
McNemar’s test.
†Active TB was diagnosed in two, one in each age group 0–1 and 2–4 years.
https://doi.org/10.1371/journal.pone.0204554.t004
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medians (S2 Fig). However, symptomatic children aged below two showed a significantly
reduced median of 4 mm (C-Tb, p<0.0001, One Way ANOVA) and 10 mm (TST, p<0.0001)
respectively, indicating that indurations were influenced by symptoms in the youngest chil-
dren (S2 Fig and S10 Table). Further, the positivity rates for both agents were significantly
lower in symptomatic children <5 years old compared to asymptomatic children (Table 4, χ2,
p<0.05). Of note, the median C-Tb induration among TB symptomatic responders was 20
Fig 3. Test positivity rates in different subgroups of children comparing TST and C-Tb along an exposure
gradient. Healthy control group (5–11 years, n = 100), asymptomatic PTB contacts<5 years (n = 87) and active TB
cases<18 years (n = 15, no HIV-infected). Error bars indicate 95% CI.
https://doi.org/10.1371/journal.pone.0204554.g003
Table 5. Injection site reactions in the full analysis set.
C-Tb (N = 1188) TST (N = 1190)
All reactions 282 (23.7) 290 (24.4)
Pruritus 210 (17.7) 221 (18.6)
Pain 90 (7.6) 81 (6.8)
Rash 58 (4.9) 63 (5.3)
Vesicles 24 (2.0) 24 (2.0)
Induration 15 (1.3) 8 (0.7)
Swelling 5 (0.4) 4 (0.3)
Erythema† 3 (0.3) 3 (0.3)
Observations are presented as n (%). N = total number of injections.
Induration50 mm.
†Erythema80 mm.
https://doi.org/10.1371/journal.pone.0204554.t005
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mm irrespective of race (394 of Black African ancestry; 111 mixed European/African,
p = 0.4520). TST showed a median of 20 mm in participants of Black African ancestry
(n = 483), and was significantly reduced to 17 mm in participants of mixed ancestry (n = 128,
p = 0.0335), which was associated with the higher BCG vaccination coverage of 85% in the
mixed race group compared to 70% in the group with Black African ancestry.
Safety
No serious AEs related to either of the skin tests were observed by the investigators. More than
95% were of mild-moderate intensity. A quarter of the participants experienced at least one
ISR from both agents (Table 5).
C-Tb showed similar types and frequencies of ISRs as TST, of which pruritus, pain, and
rash were the most common. Injection site reactions appeared most frequently among
responders, indicating that the reactions were inevitable parts of the delayed-type hypersensi-
tivity reaction. Hence, adults showed more ISRs than children, and HIV-uninfected more than
HIV-infected (not shown). No haematoma were reported with C-Tb.
A total of 338 (28%) participants reported 550 systemic AEs, of which headache (107
[9.0%]) and pyrexia (29 [2.4%]) were the most common.
Discussion
In this phase III trial we found that C-Tb had similar sensitivity compared to the TST and
QFT, both in children and HIV co-infected persons with active TB. C-Tb also had similar test-
positivity compared to QFT and TST in those with presumed LTBI (i.e. non-TB). These results
support the cut-point of C-Tb determined in adults [12,13] may also be applied in children
and in HIV-infected individuals. Separate dose-finding and sensitivity trials from the outset
(initial phase 1, 2 and 3 trials) would not have been feasible in infants and children due to the
paucibacillary nature of TB, their inability to expectorate, and frequent occurrence of extrapul-
monary TB [18]. Hence, the need for the current trial in these vulnerable, and often neglected
subgroups of patients. Indeed, one of the strategies strongly recommended by WHO to elimi-
nate TB worldwide is systematic testing and treatment of LTBI in people living with HIV, in
children, and now also in adolescents and adults, who are in close contact with PTB cases
[3,19]. The major potential advantages of C-Tb in endemic countries would be: (i) lack of the
need for laboratory facilities equipped with plate readers; these are in short supply and where
they exist there is no additional capacity; (ii) lack of the need for additional technicians which
are already in short supply; (iii) lack of the need for phlebotomy which is a major hurdle in
children; (iv) lack of the need for a transport infrastructure which is already overburdened;
(iv) easier test operation by existing health care workers; (v) substantially lower cost (although
not yet finalised the tiered pricing for C-Tb will be competitive with TST; current cost of an
IGRA to the privately paying end user in South Africa is ~US$ 77 and ~ US$ 10 for the TST
[20]).
In keeping with earlier preliminary findings [13], all three tests showed reduced sensitivities
in those with CD4 T cell counts below 100 cells/μL, reflecting that the tests relies on competent
immune function. The cut-points of TST (5 mm in HIV-infected, 15 mm in others) and C-Tb
(5 mm applied in the present trial) were validated in earlier trials [12,13] and in a separate trial
that will report a sensitivity of C-Tb similar to TST and QFT (Aggerbeck, in preparation). In
the present trial, the positivity rate of C-Tb was similar to TST and QFT except in HIV-
infected non-TB participants where C-Tb appeared more sensitive than QFT (but less sensitive
than TST) due to a high number of indeterminate results. The reasons for this observation
remain unclear but may be related to incubation time with antigen (higher with skin tests) and
C-Tb in children and HIV-infected persons
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antigen diversity and load (higher with TST). TST showed the same median induration among
HIV-infected and HIV-uninfected responders (induration1 mm), indicating that a reduced
positivity rate among HIV-infected persons is driven by the increased number of non-
responders. These non-responders would have remained test-negative even if a 5 mm cut-
point was applied, however the specificity (63%) would be reduced, as reported previously
[8,12,21].
One third of the asymptomatic childhood contacts of PTB aged<5 years old tested positive
with C-Tb and TST; it is likely that these children may benefit from LTBI treatment [3]. QFT
was not done in this age group and in accordance with WHO recommendations and the reluc-
tance by this group to accept phlebotomy [22–24]. Among symptomatic children <5 years old
the test-positivity rate of C-Tb and TST was significantly reduced compared to asymptomatic
children. Furthermore, the median induration size was reduced, especially in children aged
below two. This may be due to the immune-suppressive effect of TB itself, highlighting the
need to carefully interpret a negative test result. Consequently, although not investigated in the
present trial, in some cases, a repeat test may be considered after 2–3 months on treatment for
active TB when the severe illness has resolved [15]. We have previously shown that a repeat
test with C-Tb may be feasible [25].
There are several limitations to our trial, including the inherent difficulties in diagnosing
active TB in children resulting in misclassification bias (a limitation in all diagnostic trials in
children). Indeed, among all paediatric cases reported from 2000 to 2009 in the EU region,
only 17% were culture-confirmed [26]. In this trial, QFT had a high percentage (14%) of inde-
terminate results, resulting in a low test positivity rate in HIV-infected persons. However, a
pooled rate of 15% indeterminate results have been reported from high burden countries [27],
and high indeterminate rates have been associated with low CD4 counts [28]. Moreover, the
test was done by an ISO 15189 certified laboratory, and with a stringent quality assurance sys-
tem. For example, date and time when samples were collected and received at the laboratory
were recorded in addition to incubation conditions as part of the laboratory standard operat-
ing procedures. This revealed five cases incubated at an elevated temperature (these results
were recorded as missing), and five samples were delayed during transport. It is well known
that delays in incubation or a problem in one of the other steps may contribute to the number
of indeterminate results [11]. Of note, both skin tests classified one third of the 125 QFT inde-
terminate results as M.tb infected cases, indicating that simple skin tests may be more suitable
than laboratory-dependent tests in resource constrained settings. High QFT sensitivity has
been reported in low TB endemic countries [29,30].
We measured sensitivity in active TB. However, as there is no reference standard to diag-
nose LTBI, sensitivity can only be measured in active TB, and only comparative descriptive sta-
tistics (comparing positivity of C-Tb, QFT, and TST) provided in those with non-TB.
Alternatively, in the absence of a gold standard, the sensitivity and the specificity of any two
tests may be estimated from groups with different prevalence using a latent class model
[31,32], although such estimates may be biased if the tests have different sensitivities in the var-
ious subgroups as reported here. Moreover, such an approach is still an approximation and
can never compensate fully for lack of a gold standard. Although we could not detect any dif-
ference in test positivity rates between C-Tb and QFT (excluding indeterminate results), it is
possible that small but significant differences could have been missed given the limited sample
size. However, the study was primarily powered to detect rare adverse events and not small but
potentially significant inter-group differences. Finally, if it is hypothesized that C-Tb (contain-
ing RD-1 antigens only) is a more specific test than TST, then positivity rates of C-Tb in the
non-TB group should be lower than TST (which was not the case). We believe this is due to
the lack of a BCG confounding effect when given at birth. Indeed, a systematic review
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involving over 240 000 participants enrolled in 24 trials found that the effect of BCG vaccina-
tion on TST, when given at birth (the South African practice), was minimal at the 15 mm cut-
point [8,33,34].
There was significant racial disparity in the healthy control group (none were Black Afri-
can); this inadvertently arose due to the population distribution of the sites where the healthy
controls were recruited. However, in all the children (excluding the healthy controls) the C-Tb
induration size was similar in those of Black African and mixed ancestry. A higher number of
responders (but lower median TST induration) was observed in participants of mixed race,
which could reflect the higher BCG vaccination coverage in participants of mixed race (85%)
compared to Black Africans (70%) [6].
In conclusion, C-Tb has a similar sensitivity compared to TST and QFT in adults and chil-
dren with active TB or presumed LTBI using a universal 5 mm cut-point. In HIV-infected per-
sons C-Tb appeared more sensitive than QFT. These informative data could be valuable for
clinical practice in the future, suggesting that C-Tb may be a useful tool to guide LTBI-specific
treatment as outlined in the WHO End TB Strategy [3,16].
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